IMPORTANCE Loss of O 6 -methylguanine-DNA methyltransferase (MGMT) protein expression has been reported in several malignant tumors and predicts dismal survival outcomes. In gastric cancer, existing studies on this topic are limited and the association between MGMT and fluorouracil-based adjuvant chemotherapy remains obscure.
M ost of the developed countries in North America and northern Europe have seen a steady decline in gastric cancer incidence and mortality rates in the past 60 years. 1 In a less developed country such as China, however, gastric cancer still ranks as the second most common cancer diagnosed and is a leading cause of cancer death. 2 As the only feasible curative treatment, surgical resection is generally advised for patients with gastric cancer. 3 Unfortunately, the rate of relapse is high among patients with advanced gastric cancer, to whom adjuvant chemotherapy based on fluorouracil is commonly given as a first-line postoperative treatment. 4 As one of the most commonly used antineoplastic agents, fluorouracil has been applied for the treatment of various cancers in the past 40 years and remains the standard first-line choice for adjuvant chemotherapy. 5 However, the role of adjuvant therapy in gastric cancer is controversial because many randomized clinical trials have found it lacking survival benefit. 6 Thus, an urgent need exists for further classification of gastric cancer, one that can accurately be correlated with patient outcomes and treatment response.
The O
6
-methylguanine-DNA methyltransferase (MGMT), also known as O 6 -alkylguanine-DNA alkyltransferase, 7 is a protein that in humans is encoded by the MGMT gene (OMIM NM_002412.4) and functions as a DNA repairer capable of removing methyl groups and larger adducts at the O 6 position of guanine. 8 Through a reaction where each lesion is repaired at the cost of 1 MGMT molecule being inactivated, MGMT can transfer the alkyl group from the O 6 position of guanine in DNA to an active cysteine within its own sequence. 8, 9 Because the mutation or deletion of the MGMT gene is not common, lack of MGMT may consequently result from changes that do not alter the genetic information within the cell. 7 In humans, DNA methylation is the primary type of such epigenetic modifications and ultimately can lead to tumorigenesis. 10 Methylation of generally unmethylated sites, known as cytidine phosphate guanosine islands, in the promoter regions of tumor-suppressor and DNA-repair genes has proven to be correlated with the loss of expression of these genes within cancer cell lines and primary tumors. 10 In the MGMT gene, methylation of the cytidine phosphate guanosine island can prevent gene transcription, and in cell lines that are unable to repair alkylation of O 6 -methylguanine, the promoter of MGMT is always observed methylated. 8, 11 Methylation of the MGMT gene has been reported in several malignant tumors. In gliomas and colorectal cancers, MGMT gene methylation was found in 38% of the tumor, whereas in nonsmall cell lung carcinomas, head and neck carcinomas, and lymphomas, MGMT gene methylation was confirmed in 23% to 28% of tumors. 8, 12 However, the association of MGMT expression with gastric cancer was still obscure, and precise mechanisms underlying MGMT in gastric cancer progression required further investigation.
We conducted a study to determine whether MGMT expression could be used as an independent prognosticator for patients with resectable gastric cancer and whether MGMT could identify the patients who might benefit more from typical postoperative fluorouracil-based adjuvant chemotherapy. These results may shed light on the clinical importance of MGMT in gastric cancer and provide a possible predictive system to evaluate outcomes for patients with gastric cancer.
Methods

Patients and Tissue Samples
We recruited a cohort of 445 consecutive patients with resectable gastric cancer who underwent radical gastrectomy with standard D2 lymphadenectomy in Zhongshan Hospital at Fudan University in Shanghai, China, between August 1, 2007, and December 30, 2008. The Clinical Research Ethics Committee of Zhongshan Hospital approved this study, and patients provided written informed consent before surgery for the use of their resected samples. Data and specimens were collected from patients from the date of surgery to April 25, 2014. Data analysis took place from May 9, 2016, to July 15, 2016.
Clinicopathological characteristics and measures, including age, sex, tumor localization, tumor size, differentiation, Lauren classification, 13 and TNM stage, were retrospectively collected from each patient enrolled in the study. The specimens were evaluated independently by 2 of us who were gastroenterology pathologists (H. Liu and H. Li) blind to patients' clinicopathological data, and the TNM staging system was evaluated according to the 2010 American Joint Committee on Cancer (AJCC) and International Union Against Cancer TNM staging system. 14 The cohort was randomly divided into 2 independent data sets: the discovery data set (n = 200) and the validation data set (n = 245 
Key Points
Questions What role does the O 6 -methylguanine-DNA methyltransferase (MGMT) protein expression play in gastric cancer, and do MGMT-positive and MGMT-negative tumors respond differently to fluorouracil-based adjuvant chemotherapy?
Findings In this study involving 445 postoperative patients with resectable gastric cancer, positive expression of MGMT was an independent, favorable prognostic factor and identified a subgroup of patients with stage II disease who could benefit more from fluorouracil-based adjuvant chemotherapy.
Meaning
In resectable gastric cancer, detection of MGMT may be of use to prognosis prediction, and fluorouracil-based adjuvant chemotherapy is especially recommended for patients with stage II, MGMT-positive gastric cancer.
Patients were observed from date of surgery until April 25, 2014. The median (range) follow-up time was 49 (2 -76) months for the discovery data set and 43 (2 -79) months for the validation data set. Gastric cancer tissues were collected from the gastrectomy specimens of the 445 patients, and noncancerous gastric tissues were obtained from the gastrectomy specimens of adjacent gastric cancer margins within 5 cm. All tissues were formalin-fixed and paraffinembedded samples.
Tissue Microarray and Immunohistochemistry
Before the construction of tissue microarrays, 4-μm-thick sections were sliced from each tissue block and stained with hematoxylin-eosin for diagnostic confirmation and selection of the representative area for each tumor tissue. Then, tissue microarray blocks containing both tumor tissues and noncancerous gastric tissues were prepared by means of the method described previously 15 (eMethods 1 in the Supplement). The entire set of tissue specimens was processed and immunostained at the same time to guarantee an objective comparison between samples. Immunohistochemistry was performed as described elsewhere 15, 16 (eMethods 2 in the Supplement).
Evaluation of Immunostaining Intensity
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Step 2 Assessment of MGMT prognostic effect through time-dependent AUC Time-dependent AUC curves constructed for all 445 patients on the basis of MGMT expression and TNM stage
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Received ACT Did not receive ACT A cohort of 445 consecutive patients with resectable gastric cancer who underwent radical gastrectomy was enrolled in this study. The association between O 6 -methylguanine-DNA methyltransferase (MGMT) expression and overall survival was investigated in 2 independent, randomly assigned patient data sets: the discovery data set (n = 200) and the validation data set (n = 245). The association between MGMT protein expression and benefit from fluorouracil-based adjuvant chemotherapy was tested in a pooled database of 104 patients with TNM stage II disease and 229 patients with stage III disease from the 2 data sets. ACT indicates adjuvant chemotherapy; AUC, area under the receiver operating characteristic curve.
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Statistical Computing). All statistical analyses were 2-sided, and 2-sided P < .05 was regarded as statistically significant.
Results
Association of MGMT Expression With Clinicopathological Characteristics
This study was carried out as described in Figure 1 . The expression of MGMT was detected in 445 patients with resectable gastric cancer. Of the 445 patients included in the study, 315 (70.8%) were men, and the mean (SD) age of all patients was 60 (12) years. A total of 154 patients (34.6%) were MGMTnegative and 291 patients (65.4%) were MGMT-positive. The cohort was then randomly divided into 2 independent sets-a discovery data set (n = 200) and a validation data set (n = 245). A total of 65 patients (32.5%) in the discovery data set and 89 patients (36.3%) in the validation data set were MGMTnegative. The immunostaining for MGMT is shown in Figure 2 .
The comprehensive characteristics of patients, together with clinicopathological measures, are listed in eTable 1 in the Supplement.
Kaplan-Meier Survival Curves and Log-Rank Test Results
To discover the prognostic capability of MGMT expression in patients with resectable gastric cancer, we applied KaplanMeier survival analysis to compare OS according to MGMT expression. In both the discovery data set (hazard ratio [HR], 0.49; 95% CI, 0.30-0.79; P < .001) and the validation data set (HR, 0.58; 95% CI, 0.40-0.84; P = .002), patients with MGMT-positive expression had obviously better OS ( Figure 3 ) than those with MGMT-negative expression, indicating the potential clinical significance of MGMT for survival outcomes among patients with resectable gastric cancer. We further classified patients into an early-stage (TNM stage I) disease subgroup or an advanced-stage (TNM stage II or III) disease subgroup. Our analysis, which was validated, showed that OS was significantly better among the 96 patients in the discovery data set who were stage II or III with MGMT-positive tumors (HR, 0.52; 95% CI, 0.32-0.84; P = .003; Figure 3A ). In the validation data set, we also observed such a phenomenon among the 115 patients with MGMT-positive tumors (HR, 0.63; 95% CI, 0.43-0.93; P = .01; Figure 3B ). However, in stage I disease, neither the discovery data set nor the validation data set showed a significant difference in OS between MGMT-positive and MGMT-negative patients (HR, 0.64; 95% CI, 0.10-4.15; P = .61, and HR, 0.42; 95% CI, 0.11-1.63; P = .16; Figure 3 ). Consequently, MGMTpositive expression might act as a favorable prognostic factor for TNM stage II or III resectable gastric cancer.
Cox Proportional Hazards Regression Analysis
After the tests of proportional hazards assumption (eTable 2 in the Supplement), we performed a multivariate Cox regres- All specimens were stained using the immunohistochemistry techniques described in eMethods 2 of the Supplement and had an original magnification of ×200. Kaplan-Meier analysis of overall survival was performed on the basis of MGMT expression in patients with resectable gastric cancer. The association between MGMT expression and overall survival was investigated in a discovery data set (A) and a validation data set (B). In the discovery data set, patients with stage II or III disease had better overall survival if the tumor was MGMT-positive (hazard ratio [HR], 0.52; 95% CI, 0.32-0.84; P = .003), whereas in the stage I subgroup, no substantial difference in the overall survival was observed between patients with MGMT-positive tumors and those with MGMT-negative tumors (HR, 0.64; 95% CI, 0.10-4.15; P = .61). The result of the validation data set was consistent with that of the discovery data set. reliable, independent, favorable molecular prognosticator of OS for patients with resectable gastric cancer.
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Prognostic Power for MGMT Expression
After MGMT expression and TNM stage were proved to be 2 independent prognosticators, we sought to assess whether the incorporation of MGMT into the current TNM staging system would improve the prognostic power of MGMT. Prognostic capability was compared with the use of time-dependent AUC.
As shown in eFigure 1 in the Supplement, the AUC of MGMT was lower than the AUC of the TNM stage. However, the incorporation of MGMT into TNM stage showed better prognostic power in OS than TNM stage or MGMT alone. To build a more informative prognostic model, we established a nomogram that includes age, Lauren classification, and differentiation, besides TNM stage and MGMT (eFigure 2 in the Supplement). The prognostic nomogram performed well in postoperative OS for patients with gastric cancer, and the accuracy of this forecast was supported by the C-index (0.70) and the calibration curves (eFigure 3 in the Supplement).
MGMT Expression and Fluorouracil-Based Adjuvant Chemotherapy Benefit
Furthermore, we investigated whether patients with MGMTpositive or MGMT-negative tumors could benefit from postoperative adjuvant chemotherapy. A test for an interaction between MGMT expression and adjuvant chemotherapy indicated that, in stage II disease, the benefit from fluorouracilbased adjuvant chemotherapy was superior among patients who had MGMT-positive (HR, 0.35; 95% CI, 0.13-0.95; P = .007 for interaction; Table 2 ) tumors than among those with MGMTnegative tumors. However, the interaction test in stage III disease did not show significant results between patients who with MGMT-positive tumors (HR, 0.28; 95% CI, 0.17-0.46; P =.08 for interaction; Table 2 ) and those with MGMT-negative tumors. The corresponding Kaplan-Meier survival curves for patients with stage II or stage III disease, which comprehensively compared positive with negative MGMT expression by treatment, are reported in eFigure 4 in the Supplement. Consequently, these results suggest that patients with stage II, MGMT-positive tumors and all patients with stage III disease could benefit from fluorouracil-based adjuvant chemotherapy.
Discussion
Functioning as a DNA repair enzyme, MGMT can rapidly repair adducts at the O 6 position of guanine and act with the DNA mismatch-repair (MMR) system. 17 Previous studies were mainly focused on the role MGMT played in neural tumors. The silencing of the MGMT gene or the methylation of the MGMT As a kind of antimetabolite drug, fluorouracil is generally applied as a first-line postoperative adjuvant treatment for patients with advanced gastric cancer. 4 The antineoplastic mechanism of fluorouracil is mainly dependent on inhibiting crucial biosynthetic processes or incorporating itself into macromolecules as DNA or RNA to interfere with their normal biological function. 26 To our knowledge, no study has reported the explicit association between MGMT expression and benefit from fluorouracil-based adjuvant chemotherapy in gastric cancer. However, it was previously proved that the MMR system is involved in the effectiveness of fluorouracil. In colon cancer, MMR-deficient cancer cell lines losing expression of hMLH1 (OMIM U07418.1) were reported to show significantly more tolerance to fluorouracil than the chromosomal transfer-established, MMR-proficient HCT116+chr3 cells, indicating that the deficiency of DNA MMR might act as a key mechanism for tumor resistance to fluorouracil. 27 In addition, defective DNA MMR can make tumor cells tolerant to mismatched base pairing, and mutations in p53 as well as overexpression of antiapoptotic protein such as Bcl-2 or Bcl-X L may ultimately result in resistance to proapoptotic signals. 28 Consequently, fluorouracil responsiveness might be much more complicated than initially thought. This fluorouracil-based adjuvant chemotherapy research recruited patients stratified as having late-stage (stage II or III) gastric cancer. To prevent excessive toxic effects, we believed it was important to identify patients who might benefit the most from postoperative adjuvant chemotherapy. Consequently, we further investigated the association between the clinical outcomes of patients with MGMT-negative or MGMTpositive cancer and fluorouracil-based adjuvant chemotherapy. As a result, patients with stage II, MGMT-positive gastric cancer enjoyed a significant survival benefit from fluorouracil-based adjuvant chemotherapy, whereas patients with stage II, MGMT-negative gastric cancer did not. This result suggests that MGMT could be an important factor for anticipating the responsiveness of fluorouracil-based chemotherapy in stage II disease. This finding will be of much use for better selection and treatment of patients recommended to receive adjuvant chemotherapy.
Limitations
This study has several limitations. It is retrospective in nature, and the number of patients who received adjuvant chemotherapy is relatively small. In addition, the full chemotherapy details might not be available for the entire cohorts. Therefore, validation of these results still require a prospective, larger, multicentered randomized trial.
Conclusions
This study clarified that positive expression of MGMT in gastric cancer was an independent, favorable prognostic factor. Combining MGMT expression with the current TNM staging system could improve MGMT's prognostic capacity. Positive expression of MGMT also identified a subgroup of patients with stage II disease who could benefit from fluorouracil-based adjuvant chemotherapy. These findings pave the way for individual chemotherapy in patients with gastric cancer, but these results need to be validated given the retrospective and exploratory design of our study. We advocate for the confirmation of these findings within the framework of randomized clinical trials associated with genomic DNA sequencing studies. Tissue cylinders which were 2 mm in diameter were punched out from the targeted area of each tissue block and transferred into a recipient block with the use of a TMA instrument. Subsequently, 4-m thick sections were consecutively sliced from each of the TMA blocks. As to each TMA block, one of the sections was stained with H&E for histological verification so as to ensure the arrayed tumor tissues were adequately established. Qualified samples were defined as those where the tumor tissue accounted for more than 10% of the core area. Sections were then placed on microscope slides for immunohistochemistry.
eMethods 2. Immunohistochemistry
The TMA slides were baked at 60 for 6 hours, deparaffinized in xylene (three times, 15 min each, room temperature) and rehydrated in graded alcohol. Endogenous peroxidase was blocked with 3% H 2 O 2 in methanol at 37 for 30 minutes. Next, the slides were immersed in 0.01 M citrate buffer (pH 6.0), cooked for antigen retrieval and then incubated with 10% normal goat serum at 37 to reduce nonspecific reactions. Subsequently, mouse monoclonal antibody to human MGMT (1:300 dilution, ab39253, Abcam, Cambridge, UK) was applied to incubate the slides overnight at 4 . After rinsing 3 times with 0.01 M phosphate buffer (pH = 8.0), the slides were incubated with secondary antibody for 20 minutes at 37 and stained with the use of diaminobenzidine (DAB)-H 2 O 2 . Ultimately, the TMA slides were counterstained with hematoxylin, dehydrated, and mounted with a coverslip and neutral resins. Linear Predictor The calibration curve for predicting gastric cancer patient overall survival (OS) at (A) 3 years and (B) 5 years. Nomogram-predicted probability of OS is plotted on the horizontal axis; actual observed OS is plotted on the vertical axis.
